Why Novavax, Inc. (NASDAQ:NVAX) Stock Jumped Over 14%?


In the last trading session, the stock price of Novavax, Inc. (NASDAQ:NVAX) gained over 14% to close the session at $1.62 on more than normal volume. No specific news accounts for this move. Last month, it commenced a Phase II clinical study evaluating the immunogenicity and safety of its F-protein nanoparticle “RSV F” medication in people at least 60 years old.

The study enrolled 300 subjects, and it will assess the performance of one-dose and two-dose regimens of “RSV F” drug administered without and with aluminum phosphate or the firm’s Matrix-M adjuvant. Top-line report is anticipated in the third quarter of 2017. RSV infection is a notable risk for older people, spreading over 2.5 million Americans annually, resulting in 16,000 deaths and 207,000 hospitalizations. There are presently no RSV drugs commercially available.

The buzz

Novavax reported the commencement of a Phase II clinical study of its RSV F Vaccine in older adults, 60 years of age and more. The goal of the study is to assess immunogenicity and safety to one and two dose administration plans of the RSV F Vaccine, without and with aluminum phosphate or company’s Matrix-M™ adjuvant, in older subjects.

The study is a randomized, placebo-controlled, observer-blinded trial intended to register up to 300 older patients in the Southern Hemisphere. Subjects are being registered and vaccinated external of the RSV season to best evaluate immunogenicity.

Stanley C. Erck, the President and CEO of Novavax, reported that they consider that a more immunogenic drug in the older subject population should make into an efficacious vaccine. They anticipate the drug from this study to inform the next measures in older adults’ plan, and would ensure they maintain their leadership position in this attractive market opportunity.

Respiratory syncytial virus is a respiratory infectious problem that results in grave infection of the respiratory tract, just like influenza. For some, it may grow in severity, and result in hospitalization or even death. The RSV spread occurs yearly, with an incidence pace of 2.5 million infections yearly in the U.S., RSV is progressively being known as a major cause of mortality and morbidity in the population of as many as 64 million older adults.

This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.